564 related articles for article (PubMed ID: 23916847)
21. Whole-genome DNA methylation and gene expression profiling in the livers of mice with nonalcoholic steatohepatitis.
Bi H; Zhou B; Yang J; Lu Y; Mao F; Song Y
Life Sci; 2023 Sep; 329():121951. PubMed ID: 37473799
[TBL] [Abstract][Full Text] [Related]
22. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
23. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
24. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
[TBL] [Abstract][Full Text] [Related]
25. Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization.
Chalasani N; Toden S; Sninsky JJ; Rava RP; Braun JV; Gawrieh S; Zhuang J; Nerenberg M; Quake SR; Maddala T
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G439-G449. PubMed ID: 33501884
[TBL] [Abstract][Full Text] [Related]
26. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
27. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
[TBL] [Abstract][Full Text] [Related]
28. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD).
Raszeja-Wyszomirska J; Szymanik B; Ławniczak M; Kajor M; Chwist A; Milkiewicz P; Hartleb M
BMC Gastroenterol; 2010 Jun; 10():67. PubMed ID: 20584330
[TBL] [Abstract][Full Text] [Related]
29. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
[No Abstract] [Full Text] [Related]
30. Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Osganian SA; Subudhi S; Masia R; Drescher HK; Bartsch LM; Chicote ML; Chung RT; Gee DW; Witkowski ER; Bredella MA; Lauer GM; Corey KE; Dichtel LE
Growth Horm IGF Res; 2022 Aug; 65():101482. PubMed ID: 35780715
[TBL] [Abstract][Full Text] [Related]
31. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.
Brunt EM; Kleiner DE; Wilson LA; Unalp A; Behling CE; Lavine JE; Neuschwander-Tetri BA;
Hepatology; 2009 Mar; 49(3):809-20. PubMed ID: 19142989
[TBL] [Abstract][Full Text] [Related]
32. Histopathology of nonalcoholic fatty liver disease.
Brunt EM; Tiniakos DG
World J Gastroenterol; 2010 Nov; 16(42):5286-96. PubMed ID: 21072891
[TBL] [Abstract][Full Text] [Related]
33. Association of Hepatic Global DNA Methylation and Serum One-Carbon Metabolites with Histological Severity in Patients with NAFLD.
Lai Z; Chen J; Ding C; Wong K; Chen X; Pu L; Huang Q; Chen X; Cheng Z; Liu Y; Tan X; Zhu H; Wang L
Obesity (Silver Spring); 2020 Jan; 28(1):197-205. PubMed ID: 31785086
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease.
Charlton M; Viker K; Krishnan A; Sanderson S; Veldt B; Kaalsbeek AJ; Kendrick M; Thompson G; Que F; Swain J; Sarr M
Hepatology; 2009 Apr; 49(4):1375-84. PubMed ID: 19330863
[TBL] [Abstract][Full Text] [Related]
35. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
36. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
37. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
[TBL] [Abstract][Full Text] [Related]
38. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.
Kowdley KV; Belt P; Wilson LA; Yeh MM; Neuschwander-Tetri BA; Chalasani N; Sanyal AJ; Nelson JE;
Hepatology; 2012 Jan; 55(1):77-85. PubMed ID: 21953442
[TBL] [Abstract][Full Text] [Related]
39. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.
Loomba R; Gindin Y; Jiang Z; Lawitz E; Caldwell S; Djedjos CS; Xu R; Chung C; Myers RP; Subramanian GM; Goodman Z; Charlton M; Afdhal NH; Diehl AM
JCI Insight; 2018 Jan; 3(2):. PubMed ID: 29367468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
